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Abstract
Cell therapy for disorders of the central nervous system has progressed to a new
level of clinical application. Various clinical studies are underway for Parkinson's disease, stroke, traumatic brain injury, and various other neurological diseases. Recent
biotechnological developments in cell therapy have taken advantage of the technology of induced pluripotent stem (iPS) cells. The advent of iPS cells has provided a
robust stem cell donor source for neurorestoration via transplantation. Additionally,
iPS cells have served as a platform for the discovery of therapeutics drugs, allowing
breakthroughs in our understanding of the pathology and treatment of neurological
diseases. Despite these recent advances in iPS, adult tissue‐derived mesenchymal
stem cells remain the widely used donor for cell transplantation. Mesenchymal stem
cells are easily isolated and amplified toward the cells' unique trophic factor‐secretion property. In this review article, the milestone achievements of cell therapy for
central nervous system disorders, with equal consideration on the present translational obstacles for clinic application, are described.
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1 | I NTRO D U C TI O N

stem cells may serve as the foundation of the therapeutic effects
of cell therapy. Several activators of this endogenous repair mecha-

Cell therapy for central nervous system (CNS) disorders offers var-

nism like exogenous stem cells, electrical/magnetic stimulation, and

ious therapeutic potentials (Figure 1).1,2 First, the transplantation

other stimulatory cues enhance the innate regenerative ability of the

of exogenous cells, which include various stem/progenitor cells

CNS.4-7 Awakening of the hibernating stem cells in the hippocam-

and differentiated cells, such as neural cells committed to specific

pus, subventricular zone, or other discreet areas in the brain; accel-

phenotype, including astrocytes, and oligodendrocytes, is readily

eration of the new cell growth in proliferative niches; enhancement

referred to as a form of cell therapy. Transplanted cells may func-

of stem cells migration to the required region; and augmentation of

3

tion as part of a newly developed network in the host tissue or

differentiation in the targeted cells may afford powerful therapeu-

secrete several trophic factors with subsequent neuroprotective/

tic effects. Third, immunomodulation may be achieved by cell ther-

neurorestorative capacity.4 Second, the activation of endogenous

apy. Accumulating studies have demonstrated reduced immune and

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
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F I G U R E 1 Therapeutic potentials
of cell therapy are shown. 1.
Neurorestoration, either by cell
replacement or neural circuitry repair,
is achieved by cell transplantation.
2. The activation of endogenous
neurogenesis, as well as angiogenesis
and vasculogenesis, provides a
reservoir of proliferating new cells. 3.
Systemic/local immunomodulation is
one of the key factors on cell therapy.
4. Stem cell–based tools serve as drug
discovery and screening of disease
pathology, broadly representing
another application of cell therapy

inflammatory responses resulting from cell therapy,8 indicating reg-

been pursued to develop cell therapy into a safe and effective ther-

ulation of the immune and inflammatory reactions in the damaged

apeutic strategy for PD in both basic and clinical arenas. Based on

or degenerating nervous system which can sequester the secondary

overwhelming preclinical experiments demonstrating improved

cell death. Fourth, the development of novel drugs and screening of

behavioral and histological deficits in transplanted parkinsonian an-

disease pathology via stem cell‐based tools may be viewed as one of

imals, two clinical studies of fetal nigral cell transplantation in PD

the many applications of cell therapy.9

patients were reported.13,14 For the next decade, fetal nigral cell

In this article, the current status of cell therapy is reviewed, with

transplantation was performed in the United States and Europe.

a special focus on Parkinson's disease (PD), stroke, and traumatic

However, after Freed and coworkers reported the limited efficacy

brain injury (TBI). The current obstacles to progress are then dis-

of fetal nigral cell transplantation,15 the positive momentum of this

cussed along with possible solutions and perspectives for the future

type of cell transplantation diminished. Recently, the TRANSEURO

of the stem cells in the field of CNS disorders.

trial, a European Union‐funded multicenter clinical trial of fetal nigral
cell transplantation, has invited renewed enthusiasm in cell therapy

2 | C E LL TH E R A PY FO R PA R K I N S O N ' S
DISEASE

for PD due to positive clinical outcomes for selected patients.16,17
Other than fetal nigral cell transplantation, autologous dopaminergic cells, embryonic stem cells, neural stem cells, mesenchymal stem cells (MSCs), and other cells have been considered good

Parkinson's disease is a major neurodegenerative disease caused

transplantable cell candidates. A literature search in ClinicalTrials.

by loss of dopaminergic neurons in the nigrostriatal system char-

gov, using the key terms “Parkinson's disease” and “transplantation,”

acterized by resting tremor, rigidity, akinesia, and postural reflex

revealed 29 trials (as of November 2018), although some trials are

disturbance as representative symptoms. Dopamine replacement

labeled as terminated, while the details of the other trials are un-

therapy10 in conjunction with other medications and surgical pro-

known. The cell sources for these trials involved fetal nigral cells (6),

cedures such as subthalamic nucleus deep brain stimulation11 and

embryonic stem cells (1), MSCs (6), neural stem cells (5), induced plu-

thalamotomy are established treatments for PD. However, current

ripotent stem cells (iPS cells) (1), and others (10). iPS cells may rep-

treatments focus only on the suppression of symptoms, and there

resent unique transplantable features compared with the other cell

is no treatment capable of stopping or improving the pathological

sources. In 2006, Takahashi and Yamanaka established iPS cells from

condition itself. Thus, regenerative medicine, and in particular cell

mouse embryonic and adult fibroblast cell culture by adding four

therapy, has attracted the attention of many scientists, doctors, and

factors: Oct3/4, Sox2, c‐Myc, and Klf4.18 This discovery is widely

patients, because of its potential for reinnervation of the neuronal

heralded as pivotal to the progress of cell therapy toward clinical ap-

network and neurorestoration, allowing disease‐modifying instead

plications, with many subsequent studies detailing the viability and

of palliative outcomes.1

reproducibility of iPS cells, coupled with therapeutic efficacy. The

Since Perlow and colleagues first demonstrated in 1979 that

first clinical application of iPS cells in Japan was performed by using

brain tissue grafts of dopaminergic neurons ameliorate behavioral

autologous iPS cells, which were differentiated into mature retinal

abnormalities in the rat model of PD,12 several investigations have

pigment epithelial cells, for patients with macular degeneration.19 In

|
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this study, no significant adverse events were noted at 1 year post‐

in the neurovascular unit is paramount to devising cell‐based re-

transplantation. For PD, several teams explored a therapeutic strat-

generative medicine. To this end, MSCs have shown promise in

egy using autologous iPS cell–derived neurons. 20 One of the merits

regenerating the neurovascular unit. The advantages of MSCs

of autologous cells is they circumvent ethical issues associated with

are (a) rapid isolation from bone marrow, (b) efficient amplifica-

fetal and embryonic cells. Additionally, such same donor‐recipient

tion in culture, (c) easy maintenance in culture, (d) suitability for

of the stem cells may avoid immunological problems. However, the

autologous transplantation even in the acute phase of stroke, and

logistics in establishing a homogenous population of iPS cells with

(e) solid neurotrophic effects. 25 The therapeutic effects of MSCs

phenotypic profile and functionality of a dopaminergic neuron re-

may be mediated by many regenerative mechanisms, which in-

main a challenge toward clinical application. Moreover, the harvest

clude angiogenesis, anit‐inflammation, antiapoptosis, neurogen-

of iPS cells from PD patients may present with cells containing the

esis with subsequent cell migration, and differentiation. 26 Due

disease pathology, thus may succumb to accelerated neurodegener-

to their long‐track record of safety in hematologic diseases and

ation as opposed to iPS cells derived from healthy donors. To over-

a bulk of preclinical stroke studies demonstrating safety and ef-

come these problems related to autologous iPS cells, nonautologous

ficacy, MSCs have been the focus of many clinical studies. Cell de-

iPS cell–derived cells may be an alternative transplantable source;

livery of MSCs entails intracerebral, intra‐arterial, or intravenous

however, immune reactions are likely to arise with the use of mis-

route. 27 An intracerebral approach may be the most effective,

matched donor cells. Ensuring the quality of the phenotype and

but also the most invasive, while an intravenous approach may be

function of the differentiated iPS cells should be approached in tan-

the least invasive but with the fewest cells reaching the targeted

dem with the safety of both autologous and nonautologous iPS cells.

area in the brain. The intra‐arterial approach may lie somewhere

A recent study demonstrated that iPS cells from several specified

between the two cell delivery routes. In 2005, a phase I study

human leukocyte antigen (HLA)‐homozygous donors display no de-

with an intravenous administration of autologous MSCs was first

tectable immune rejection, suggesting their potential as safe and ef-

performed for patients with ischemic stroke. 28 In 2014, the first

fective donor cells. 21 In Japan, specified allogeneic iPS cell–derived

phase II clinical trial involving intravenous administration with al-

dopamine neurons have been generated under high‐safety proto-

logeneic MSCs for patients with ischemic stroke was published. 29

cols.

22

Very recently, a Japanese team successfully implanted for the

In this study, the therapeutic effects of intravenous administra-

first time dopamine neurons derived from allogeneic iPS cells into a

tion of allogeneic MSCs were reported for patients with ischemic

PD patient (https://www.nature.com/articles/d41586-018-07407-

stroke in the subacute phase. In a study using intra‐arterial allo-

9). An international organization focusing on safety of cell transplan-

geneic MSC administration, 40% of stroke patients who receive

tation, GForce‐PD, is actively monitoring these trials (http://www.

transplantation exhibited good clinical outcomes within 3‐7 days

gforce-pd.com/). 23 Stem cell transplantation with the use of iPS cells

after onset. 29 The administration route and the timing for stroke

for PD patients has now reached another significant milestone, rem-

patients may require more optimization because of the differences

iniscent of the excitement in the 80 seconds and 90 seconds when

in stroke severity across patients. In Japan, several clinical studies

fetal cells were first implanted in PD animals and patients.

are ongoing. Shichinohe and teammates reported their protocol of
intracerebral administration of autologous MSCs in the subacute

3 | C E LL TH E R A PY FO R S TRO K E

phase of stroke. 30 They proposed to use cells labeled with superparamagnetic iron oxide for cell tracking, which may reveal the
distribution of the transplanted cells over time.

Stroke is currently one of the most examined CNS disorders for
cell therapy. A search of ClinicalTrials.gov for “stroke,” “brain,”
and “transplantation” generated 34 studies. In almost 70% of the
studies, MSCs or related cells were used. In stroke, multiple cells,

4 | C E LL TH E R A PY FO R TR AU M ATI C
B R A I N I N J U RY

including neurons, astrocytes, oligodendrocytes, and other cells,
succumb to abrupt death following the stroke onset with many

Traumatic brain injury is a common neurological disorder caused

more cells exposed to progressive degeneration due to subse-

by physical trauma to the brain that affects all ages and has long‐

quent secondary damage. 24 The disease progression is completely

lasting effects. To date, there is no effective drug treatment for

different from that of PD, which is characterized primarily by do-

TBI, and patients are often left depending on rehabilitation and

paminergic neuronal degeneration. The true restoration for stroke

symptom management, which had limited effectiveness. 31 Ideally,

is different from that for PD in that the regeneration for many

an effective treatment would be one that offers an extended ther-

types of cells, coined neurovascular unit, is required. Recognition

apeutic window and reduces secondary cell death progression.

of key cell‐to‐cell interactions as a network has been acknowl-

Furthermore, to combat the complex secondary cell degradation,

edged in stroke degeneration and regeneration. Considering the

it is necessary to have a treatment that acts through diverse mech-

multiplicity of cell types and their functions affected by stroke,

anisms in order to successfully translate to the clinic. This pre-

robust and long‐lasting regeneration for stroke appears very dif-

sents an important research prospect for regenerative medicine.

ficult under existing circumstances. The goal to arrest cell death

To this end, there is an emerging field of study that posits stem cell
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transplants as an ideal option because they can provide increased

a decrease in their expression. In this respect, treatment intended

growth factors levels, ameliorate neuroinflammation, inhibit ap-

to rescue these expression levels may circumvent the TBI‐induced

optotic pathways, offer a wide therapeutic window, and apply to a

apoptosis in the peri‐impact area.55,56 While preclinical studies of

larger number of patients.

stroke have revealed that administering stand‐alone glial cell line–

Previously, TBI was classified as an acute injury due to the lack

derived neurotrophic factor (GDNF), 57 brain‐derived neurotrophic

of understanding of the chronic functional deficits and pathological

factor (BDNF),58 vascular endothelial growth factor (VEGF),56 stem

However, TBI is now considered a chronic disease

cell factor (SCF),59 or stromal cell–derived factor (SDF)‐1α60 may

because of the secondary inflammatory response that accompanies

produce improvements on neurological outcomes, various compli-

the initial insult.32,33 Currently, there remains a dearth of clinical

cations limit the likelihood of clinical success. These complications

trials for TBI therapies, with most of the ones that do exist relying

entail determining the correct types, dosages, and timing of these

entirely on rehabilitation treatment.34-39 Since TBI is followed by a

factors and thus represent a significant challenge. Inappropriately

chronic neurodegeneration phase, more emphasis has been placed

high doses may do more harm than good; for example, drug‐induced

recently on neuroregenerative medicine rather than neuroprotec-

overproduction of BDNF has been documented to trigger epileptic

tive medicine, which may be effective only in the acute phase of the

seizures.61 To this end, stem cells possess an innate ability to re-

symptoms.

injury.

40,41

32,33

Therefore, stem cell therapy is a clear option and, indeed,

spond to the minute‐to‐minute status of their environment and ad-

has a history of inducing robust functional recovery in clinical and

just the levels of their secreted neurotrophic factors accordingly. 55

42-45

By affording an in situ source for these factors, transplanted stem

laboratory settings, including those conducted on TBI models.

Despite these merits, translating stem cell therapy to the clinic has

cells may reduce inflammation and increase cell survival.

proven to be a difficult task.46 Further investigation is warranted in

Another mechanism of action whereby stem cell transplants

order to find the mechanism by which stem cells provide regenera-

may confer indirect therapeutic effects is their activation and am-

tive properties in TBI brains, in addition to ideal treatment regimes.

plification of natural neuroprotective responses that may otherwise

Determining the optimal stem cell source is likewise essential to

remain latent or impotent. That adult brains are unable to regener-

ensure ethical clearance and graft integrity, and also to assure the

ate neurons was invalidated by recent evidence of endogenous stem

replicability and the validity observed in laboratory settings. More

cells housed in the neurogenic niches: the subgranular zone (SGZ)

research is needed to identify the optimal cell line that can be har-

of the dentate gyrus and the subventricular zone (SVZ) of the lat-

vested regularly and safely delivered to the patients. Even so, stem

eral ventricles.62,63 Therefore, under the right conditions, these cells

cells offer neuroprotective effects through multipronged pathways,

may promote neurogenesis, which could be particularly useful as a

such as those that support neurogenesis and reduce neuroinflam-

therapeutic tactic to combat neurological insults.64 However, the

mation,

47-49

while simultaneously increasing vasculogenesis and

restrained capacity of these cells to commit to a neuronal lineage,

50-52

Notably, the cytotoxic environment that exacer-

differentiate, and mobilize to the impact region from the neurogenic

bates and is produced by the secondary inflammatory response may

angiogenesis.

niches has stymied this therapeutic avenue.65 Until recently, en-

also be responsible for the low graft survival rates that have been

dogenous stem cells' largely insufficient prevention or reduction of

observed in the TBI brain.53 Nonetheless, functional recovery still

pathological pathway‐induced cell death progression has seemed to

prevails, implying that another factor besides graft survival and di-

be a dead end. Yet, exogenous stem cell transplants have unveiled

rect replacement may engender some of the recorded benefits. In

a new path to facilitate the lengthy migration of these endogenous

addition, reducing the toxicity of the microenvironment may lead

stem cells and thus allow their effects to be therapeutically relevant.

to increased graft survival and amplified neuroprotective bystander

A frontal cortex controlled cortical impact (CCI) rodent model of TBI

effects is an promising therapeutic approach for future studies with

demonstrates enhanced recovery in the group treated with intra-

the ultimate goal of translating stem cell therapy for use in the clinic.

cranially delivered MSCs compared to the vehicle group66; impor-

At first, stem cell transplants were intuitively thought to func-

tantly, according to past evidence, the frontal cortex was considered

tion in the CNS by replacing damaged neural cells with new, viable

too distant to be accessible by most endogenous stem cells. Upon

cells in a one‐to‐one fashion. As mentioned above, it has been ob-

immunohistochemical analysis and laser capture microdissection,

served that stem cell transplantation directly into the damaged tis-

however, the observation of a MSC‐paved “biobridge” linking the

sue leads to poor graft survival. Nevertheless, functional recovery

neurogenic niche and the damaged frontal cortex posits a potential

and reduced neural death have still been observed despite the poor

mechanism by which transplanted stem cells may recruit the endog-

Therefore, more complex mechanisms must be respon-

enous stem cells to injury site.66 This novel theory of a biobridge

sible for stem cells' therapeutic potential, instead of their previously

has not been observed in any procedure other than stem cell trans-

theorized long‐term survival and differentiation.

plantation and is believed to mediate the neuroprotective and neu-

retention.

54

In response, other mechanisms of action have been proposed

roregenerative actions of endogenous stem cells. Thus, transplanted

to clarify this seeming incongruity. That transplanted stem cells

stem cells and endogenous stem cells may act together to protect

may secrete neurotrophic factors represents the first of these.

and restore the TBI‐damaged brain.

These neurotrophic factors generally confer therapeutic effects

The transplanted stem cells' secretome, which constitutes

via their activation of cell survival pathways, yet TBI usually entails

the sum of their secreted factors, has been proposed as a fourth

|
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mechanism by which stem cell transplants may grant indirect ther-

for stem cell differentiation, migration, or synapse network forma-

apeutic effects after TBI. In addition to the various neurotrophic

tion, which are critical indices of CNS regeneration. In a mouse

factors produced from the corpus of the cell, stem cells may also

model of chronic spinal cord injury, improvement in allodynia and

emit exosomes and microvesicles, which, in turn, may release

hyperalgesia was observed animals that received neural stem/pro-

chemokines, cytokines, long noncoding RNA (lncRNA), microRNA,

genitor cell transplantation with rehabilitation.75 Electrical stimu-

and growth factors such as VEGF.67 That this secretome may confer

lation was also shown to trigger the migration of intracerebrally

therapeutic effects on lung, cardiovascular, liver, and kidney disease

transplanted mesenchymal stromal cells in experimentally stroke

has been supported by improvements observed after treatment of

rats through SDF‐1α signaling.7 Long‐term potentiation enhances

isolated microvesicles and exosomes obtained from multipotent

neurogenesis in the hippocampus.76,77 Additionally, electrical

MSCs.67 Furthermore, in a rodent model of TBI, the groups injected

stimulation improves synapse formation, altogether facilitating

with MSC secretome display lower levels of brain damage volume

the therapeutic effects of cell therapy and suggesting the poten-

and apoptosis, and exhibit higher levels of regenerated neurons and

tial of combined approaches.

improved scores on cognitive and motor functional assessments
when compared to the control group.68 Thus, stem cell transplants
present multiple treatment strategies that may be harnessed to improve the current standard of care for TBI patients.

6.2 | Safety of cell therapy
Autologous patient‐derived cells may circumvent logistical and ethical
problems. However, genetic engineering or reprogramming of these

5 | C E LL TH E R A PY FO R OTH E R C E NTR A L
N E RVO U S S YS TE M D I S O R D E R S

adult cells to amplify stemness can lead to uncontrolled proliferative
capacity. On the other hand, if these patient‐derived cells are left unmanipulated the disease pathology, including genetic abnormality may
limit their viability and therapeutic potential. Accordingly, careful ma-

Cell therapy for CNS disorders covers a broad range of pathologi-

nipulation of these cells is needed to ensure stemness while regulating

cal conditions, such as spinal cord injury,69 amyotrophic lateral scle-

their proliferation. Alternatively, the use of healthy donors for alloge-

rosis,70 Huntington's disease,71 and cerebral palsy.72 Psychiatric

neic may avoid the disease phenotype of cell source, but these cells run

diseases are one of the targets of cell therapy, and depression

the risk of immune rejection. To this end, there is a need to eliminate

is a common disease that is one of the major causes of disability.

uncertain factors for cell differentiation, remove cells at risks for tumo-

Although pharmacological treatment has improved, only roughly

rigenesis, and purify the differentiated cells regardless of donor origin.

50% of depressed patients respond to this method.73 Recently, we

Even after thorough testing, failsafe procedures should be confirmed

reported on the therapeutic potential of encapsulated mesenchymal

by various methods in clinical settings.78

stem cells for a depression model of rats.74 The treatment improved
depression‐like behavior with enhancement of the endogenous
neurogenesis in the hippocampus and the subventricular zone. The

6.3 | Concerns about iPS cells

activation of signaling with various trophic factors, including VEGF,

iPS cells as autologous stem cells have become an attractive cell

BDNF, ciliary neurotrophic factor, and fibroblast growth factor 2,

source for transplantation. For transition to clinical application, re-

was involved in the therapeutic effects. Thus, cell therapy might

duction in time to convert these cells into the desired cell phenotype,

offer hope for psychiatric disorders.

and the cost associated with such cell culture to establish, maintain
and use of iPS cells for therapeutic purpose are key enabling stud-

6 | CU R R E NT O B S TAC LE S TH AT H I N D E R
L A B O R ATO RY‐TO ‐ C LI N I C PRO G R E S S

ies.79 Inter‐clonal differences, nonhomogeneity of differentiation,
and varied genetic backgrounds represent additional technical issues when priming iPS cell–derived differentiated neurons, oligodendrocytes, or astrocytes as cell products for CNS disorders. Gene

Cell therapy for CNS disorders has generally advanced toward clini-

expression of dopaminergic neurons derived from iPS cells of PD pa-

cal application, but technical and logistical problems perspectives

tients was reported to be significantly different from that of primary

remain, which are discussed below.

dopaminergic neurons.80 Beyond replacement of functional cells
for patients with CNS disorders, iPS cells have broad potentials for

6.1 | Enhancement of the therapeutic effects of
cell therapy

establishing disease models that will be valuable for recapitulating
pathological conditions and subsequent drug development. In the
end, the genetic alteration, reaction to drugs, and age of the cells

Several cells are considered promising candidates for cell therapy.

limit the use of autologous patient‐derived iPS cells compared to

However, optimizing the therapeutic outcomes of transplanted

allogeneic healthy donor‐derived iPS cells. Alternatively, the direct

cells is warranted. Rehabilitation, certain pharmacologic agents,

conversion or trans‐differentiation from fibroblasts into neurons

and electrical/magnetic stimulation may serve as adjunct treat-

while skipping the iPS cell states may circumvent these technical

ments that may enhance cell therapy by providing important cues

problems.81
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therapy have been evaluated in clinical trials. The quality and well‐
defined characteristics of the stem cells are basic criteria that need
to be ascertained prior to any clinical application. Equally important
is the rigorous clinical trial design in order to ensure unbiased, re-
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producible, and valid outcomes. The primary outcomes for the trials
should be carefully considered, together with the dose, route, and
timing of cell administration. Differences in clinical trial designs have
made difficult comparing the outcomes between studies. In determining efficacy, ample consideration should also be given to evaluating safety of cell therapy. Minimally invasive procedures, such as
intravenous and intra‐arterial routes, may not present much safety
issues related to the injection site as opposed to more invasive administrations (eg, intra‐thecal, and intracerebral) which should be
performed with much greater care by a skilled clinician. A center of
excellence for regenerative medicine is likely to facilitate the regulated conduct of a clinical trial, allowing rigorous evaluation of the
safety and efficacy of cell therapy.

6.5 | Protection of patients' rights
The care of human research subjects is also extremely important.
Complications arising from the procedure itself, the transplanted
cells, and cell‐associated factors need to be closely monitored to
protect the patients participating in clinical trials, especially in the
case of invasive cell procedures. A safety monitoring board should
be tasked to perform such adverse outcome monitoring not only
during the acute post‐transplantation period but also throughout
long‐term post‐transplantation period. The control and maintenance
of privacy, including genetic information, should also be considered.
Legal systems, the insurance regimen, and the institutional review
board should be reconsidered with a focus on the education for both
doctors and patients in response to the entry of cell therapy from
small scale to a larger clinical trials.

7 | CO N C LU S I O N
Cell therapy has progressed considerably, and further advances are
being made. While the current status of cell therapy for CNS disorders is promising, we need to overcome various obstacles in the
near future.
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